Limited Edition Golden Llama is here! Check out how you can get one. Limited Edition Golden Llama is here! Check out how you can get one.
Offering SPR-BLI Services - Proteins provided for free! Get your ComboX free sample to test now!
Time Limited Offer: Welcome Gift for New Customers ! Shipping Price Reduction for EU Regions
Expression analysis of human B7-H3 (4Ig) on CHO/Human B7-H3 (4Ig) Stable Cell Line by FACS.
Cell surface staining was performed on CHO/Human B7-H3 (4Ig) Stable Cell Line or negative control cell using PE-labeled anti-human B7-H3 (4Ig) antibody.
5e5 of anti-B7-H3 CAR-293 cells were stained with 100 μL of 1:50 dilution (2 μL stock solution in 100 μL FACS buffer) of PE-Labeled Human B7-H3 (4Ig), His Tag (Cat. No. B7B-HP2H9) and negative control protein respectively. PE signal was used to evaluate the binding activity (QC tested).
Loaded Monoclonal Anti-Human B7-H3 / B7-H3 (4Ig) Antibody, Human IgG1 on Protein A Biosensor, can bind Human B7-H3 (4Ig), His Tag (Cat. No. B7B-H52E7) with an affinity constant of 1.74 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Ifinatamab deruxtecan | DS-7300; DS-7300a; MABX-9001a | Phase 3 Clinical | Daiichi Sankyo Co Ltd | Solid tumours; Small Cell Lung Carcinoma | Details |
B7-H3 CAR-T cell therapy (Boyuan Runsheng Pharma) | Phase 2 Clinical | Boyuan Runsheng Pharma (Hangzhou) Co Ltd | Solid tumours; Glioblastoma | Details | |
Obrindatamab | MGD-009; B7-H3 x CD3 | Phase 2 Clinical | Macrogenics Inc | Mesothelioma; Carcinoma, Non-Small-Cell Lung; Melanoma; Thyroid Neoplasms; Sarcoma; Neuroblastoma; Neurofibrosarcoma; Prostatic Neoplasms; Breast Neoplasms; Ovarian Neoplasms; Sarcoma, Synovial; Urinary Bladder Neoplasms; Wilms Tumor; Pancreatic Neoplasms; Colonic Neoplasms; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Rhabdomyosarcoma | Details |
Vobramitamab duocarmazine | MGC-018 | Phase 2 Clinical | Macrogenics Inc | Liver Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Anus Neoplasms; Carcinoma, Renal Cell; Small Cell Lung Carcinoma; Carcinoma, Ovarian Epithelial; Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms; Laryngeal Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Small Cell; Carcinoma, Pancreatic Ductal; Carcinoma, Non-Small-Cell Lung; Melanoma | Details |
TAK-280 | MVC-280; TAK-280 | Phase 2 Clinical | Maverick Therapeutics Inc | Solid tumours; Neoplasms; Neoplasm Metastasis | Details |
4SCAR-276 | 4SCAR-276 | Phase 2 Clinical | Shenzhen Geno-Immune Medical Institute | Solid tumours | Details |
IBI-3001 | IBI-3001; IBI3001 | Phase 2 Clinical | Innovent Biologics(Suzhou) Co Ltd | Solid tumours | Details |
Allogenic B7H3-targeting CAR-γδT Cell Therapy | QH104 Cell; QH-104 Cell | Phase 2 Clinical | Suzhou Dushu Lake Hospital (Dushu Lake Hospital Affiliated To Soochow University) | Glioblastoma | Details |
IBI129 | IBI-129; IBI129 | Phase 2 Clinical | Innovent Biologics(Suzhou) Co Ltd | Solid tumours | Details |
7MW3711 | 7-MW-3711; 7MW3711 | Phase 2 Clinical | Mabwell (Shanghai) Bioscience Co Ltd | Solid tumours; Neoplasms | Details |
IBI334 | IBI334; IBI-334 | Phase 2 Clinical | Innovent Biologics(Suzhou) Co Ltd | Solid tumours; Neoplasms | Details |
MHB088C | MHB-088C | Phase 2 Clinical | Minghui Pharmaceutical Pty Ltd | Solid tumours | Details |
DB-1311 | DB-1311 | Phase 2 Clinical | Solid tumours; Neoplasm Metastasis | Details | |
IBB-0979 | IBB0979; IBB-0979 | Phase 2 Clinical | SunHo (China) BioPharmaceutical Co Ltd | Solid tumours; Neoplasms | Details |
YL-201 | YL-201; YL201 | Phase 2 Clinical | MediLink Therapeutics Co Ltd | Solid tumours; Prostatic Neoplasms, Castration-Resistant | Details |
Fully Human B7H3 CAR-T Cells Therapy | fhB7H3.CAR-Ts | Phase 2 Clinical | The Affiliated Hospital Of Xuzhou Medical University | Ovarian Neoplasms; Carcinoma, Hepatocellular | Details |
CD-276-targeted Chimeric Antigen Receptor T Cell Therapy | CD276 CAR-T | Phase 2 Clinical | Shenzhen University General Hospital | Pancreatic Neoplasms | Details |
Enoblituzumab | MGA-271; TJ271 | Phase 2 Clinical | Macrogenics Inc | Carcinoma, Transitional Cell; Melanoma; Carcinoma, Non-Small-Cell Lung; Fallopian Tube Neoplasms; Peritoneal Neoplasms; Osteosarcoma; Neuroblastoma; Sarcoma, Ewing; Prostatic Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Ovarian Neoplasms; Neoplasms; Triple Negative Breast Neoplasms; Wilms Tumor; Carcinoma, Renal Cell; Desmoplastic Small Round Cell Tumor; Abdominal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Solid tumours; Rhabdomyosarcoma; Head and Neck Neoplasms | Details |
HS-20093 | HS20093; HS-20093 | Phase 2 Clinical | Shanghai Hansoh Biomedical Co Ltd | Solid tumours; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Small Cell Lung Carcinoma; Prostatic Neoplasms, Castration-Resistant; Sarcoma; Osteosarcoma | Details |
124I-omburtamab | 124I-8H9; 124I-8H9-(B7-H3) | Phase 1 Clinical | Memorial Sloan Kettering Cancer Center, Y-Mabs Therapeutics Inc | Brain Neoplasms; Glioma | Details |
Mirzotamab clezutoclax | ABBV-155 | Phase 1 Clinical | Abbvie Inc | Solid tumours | Details |
SCRI-CARB7H3 | SCRI-CARB7H3 | Phase 1 Clinical | Seattle Children'S Hospital | Neuroblastoma; Choroid Plexus Neoplasms; Neoplasms, Germ Cell and Embryonal; Melanoma; Glioma; Diffuse Intrinsic Pontine Glioma; Neuroectodermal Tumors, Primitive; Sarcoma; Sarcoma, Clear Cell; Neurofibrosarcoma; Sarcoma, Ewing; Osteosarcoma; Retinoblastoma; Teratoma; Sarcoma, Synovial; Central Nervous System Neoplasms; Wilms Tumor; Diffuse midline glioma; Hepatoblastoma; Rhabdoid Tumor; Desmoplastic Small Round Cell Tumor; Carcinoma; Rhabdomyosarcoma; Medulloblastoma; Solid tumours; Ependymoma | Details |
CC-3 | CC-3 | Phase 1 Clinical | Eberhard Karls University Of Tubingen, Germany | Colorectal Neoplasms; Gastrointestinal Neoplasms | Details |
KT-095 | KT-095 | Phase 1 Clinical | Nanjing Kati Medical Technology Co Ltd | Solid tumours | Details |
EX-105 | EX-105; EX105 | Phase 1 Clinical | Guangzhou Excelmab Inc | Solid tumours | Details |
MGC-026 | MGC026; MGC-026 | Phase 1 Clinical | Macrogenics Inc | Prostatic Neoplasms, Castration-Resistant; Uterine Cervical Neoplasms; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Melanoma; Endometrial Neoplasms; Colorectal Neoplasms; Sarcoma; Urinary Bladder Neoplasms; Ovarian Neoplasms; Neoplasms; Small Cell Lung Carcinoma; Pancreatic Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Solid tumours | Details |
Loco-regional B7H3 IL-7Ra CAR T Cell therapy(Chulalongkorn University) | Phase 1 Clinical | Chulalongkorn University, King Chulalongkorn Memorial Hospital | Brain Neoplasms; Diffuse Intrinsic Pontine Glioma | Details | |
Autologous CAR-T Cells Targeting B7-H3(Unc Lineberger Comprehensive Cancer Center) | Phase 1 Clinical | Unc Lineberger Comprehensive Cancer Center | Ovarian Neoplasms; Pancreatic Neoplasms; Carcinoma, Ovarian Epithelial; Triple Negative Breast Neoplasms; Neoplasms; Breast Neoplasms | Details | |
MT-027 | MT-027 | Phase 1 Clinical | T-Maximum Pharmaceutical (Suzhou) Co Ltd | Glioma | Details |
UTAA06 | UTAA-06 | Phase 1 Clinical | Persongen Biotherapeutics (Suzhou) Co Ltd | Leukemia, Myeloid, Acute | Details |
B7-H3 CAR T-cell therapy(Stanford University) | B7-H3CART | Phase 1 Clinical | Stanford University | Nervous System Diseases | Details |
TX103 CAR-T cell therapy(Fuzhou Tuoxin Tiancheng Biotechnology) | Phase 1 Clinical | Fuzhou Tuoxin Tiancheng Biotechnology Co Ltd | Solid tumours; Glioma | Details | |
EGFR/B7H3 CAR-T | EGFR/B7H3 CAR-T | Phase 1 Clinical | Second Affiliated Hospital Of Guangzhou Medical University | Triple Negative Breast Neoplasms; Lung Neoplasms | Details |
BAT-8009 | BAT8009; BAT-8009 | Phase 1 Clinical | Bio-Thera Solutions Ltd | Solid tumours | Details |
TAA-06 | TAA06-UCAR-γδT; TAA-06 | Phase 1 Clinical | Persongen Biotherapeutics (Suzhou) Co Ltd | Solid tumours; Neuroblastoma; Colorectal Neoplasms; Lung Neoplasms; Melanoma | Details |
XmAb-808 | XmAb808 | Phase 1 Clinical | Xencor Inc | Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Transitional Cell; Carcinoma, Ovarian Epithelial; Triple Negative Breast Neoplasms; Prostatic Neoplasms, Castration-Resistant; Colorectal Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung | Details |
Anti-CD276 CAR T-cell therapy (Persongen ) | Phase 1 Clinical | Persongen Biotherapeutics (Suzhou) Co Ltd | Stomach Neoplasms; Small Cell Lung Carcinoma; Osteosarcoma; Neuroblastoma; Lung Neoplasms | Details | |
B7-H3-targeting CAR-T cell therapy | Beijing Tiantan Hospital, Capital Medical University | Details | |||
Ifinatamab deruxtecan | DS-7300; DS-7300a; MABX-9001a | Phase 3 Clinical | Daiichi Sankyo Co Ltd | Solid tumours; Small Cell Lung Carcinoma | Details |
B7-H3 CAR-T cell therapy (Boyuan Runsheng Pharma) | Phase 2 Clinical | Boyuan Runsheng Pharma (Hangzhou) Co Ltd | Solid tumours; Glioblastoma | Details | |
Obrindatamab | MGD-009; B7-H3 x CD3 | Phase 2 Clinical | Macrogenics Inc | Mesothelioma; Carcinoma, Non-Small-Cell Lung; Melanoma; Thyroid Neoplasms; Sarcoma; Neuroblastoma; Neurofibrosarcoma; Prostatic Neoplasms; Breast Neoplasms; Ovarian Neoplasms; Sarcoma, Synovial; Urinary Bladder Neoplasms; Wilms Tumor; Pancreatic Neoplasms; Colonic Neoplasms; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Rhabdomyosarcoma | Details |
Vobramitamab duocarmazine | MGC-018 | Phase 2 Clinical | Macrogenics Inc | Liver Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Anus Neoplasms; Carcinoma, Renal Cell; Small Cell Lung Carcinoma; Carcinoma, Ovarian Epithelial; Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms; Laryngeal Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Small Cell; Carcinoma, Pancreatic Ductal; Carcinoma, Non-Small-Cell Lung; Melanoma | Details |
TAK-280 | MVC-280; TAK-280 | Phase 2 Clinical | Maverick Therapeutics Inc | Solid tumours; Neoplasms; Neoplasm Metastasis | Details |
4SCAR-276 | 4SCAR-276 | Phase 2 Clinical | Shenzhen Geno-Immune Medical Institute | Solid tumours | Details |
IBI-3001 | IBI-3001; IBI3001 | Phase 2 Clinical | Innovent Biologics(Suzhou) Co Ltd | Solid tumours | Details |
Allogenic B7H3-targeting CAR-γδT Cell Therapy | QH104 Cell; QH-104 Cell | Phase 2 Clinical | Suzhou Dushu Lake Hospital (Dushu Lake Hospital Affiliated To Soochow University) | Glioblastoma | Details |
IBI129 | IBI-129; IBI129 | Phase 2 Clinical | Innovent Biologics(Suzhou) Co Ltd | Solid tumours | Details |
7MW3711 | 7-MW-3711; 7MW3711 | Phase 2 Clinical | Mabwell (Shanghai) Bioscience Co Ltd | Solid tumours; Neoplasms | Details |
IBI334 | IBI334; IBI-334 | Phase 2 Clinical | Innovent Biologics(Suzhou) Co Ltd | Solid tumours; Neoplasms | Details |
MHB088C | MHB-088C | Phase 2 Clinical | Minghui Pharmaceutical Pty Ltd | Solid tumours | Details |
DB-1311 | DB-1311 | Phase 2 Clinical | Solid tumours; Neoplasm Metastasis | Details | |
IBB-0979 | IBB0979; IBB-0979 | Phase 2 Clinical | SunHo (China) BioPharmaceutical Co Ltd | Solid tumours; Neoplasms | Details |
YL-201 | YL-201; YL201 | Phase 2 Clinical | MediLink Therapeutics Co Ltd | Solid tumours; Prostatic Neoplasms, Castration-Resistant | Details |
Fully Human B7H3 CAR-T Cells Therapy | fhB7H3.CAR-Ts | Phase 2 Clinical | The Affiliated Hospital Of Xuzhou Medical University | Ovarian Neoplasms; Carcinoma, Hepatocellular | Details |
CD-276-targeted Chimeric Antigen Receptor T Cell Therapy | CD276 CAR-T | Phase 2 Clinical | Shenzhen University General Hospital | Pancreatic Neoplasms | Details |
Enoblituzumab | MGA-271; TJ271 | Phase 2 Clinical | Macrogenics Inc | Carcinoma, Transitional Cell; Melanoma; Carcinoma, Non-Small-Cell Lung; Fallopian Tube Neoplasms; Peritoneal Neoplasms; Osteosarcoma; Neuroblastoma; Sarcoma, Ewing; Prostatic Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Ovarian Neoplasms; Neoplasms; Triple Negative Breast Neoplasms; Wilms Tumor; Carcinoma, Renal Cell; Desmoplastic Small Round Cell Tumor; Abdominal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Solid tumours; Rhabdomyosarcoma; Head and Neck Neoplasms | Details |
HS-20093 | HS20093; HS-20093 | Phase 2 Clinical | Shanghai Hansoh Biomedical Co Ltd | Solid tumours; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Small Cell Lung Carcinoma; Prostatic Neoplasms, Castration-Resistant; Sarcoma; Osteosarcoma | Details |
124I-omburtamab | 124I-8H9; 124I-8H9-(B7-H3) | Phase 1 Clinical | Memorial Sloan Kettering Cancer Center, Y-Mabs Therapeutics Inc | Brain Neoplasms; Glioma | Details |
Mirzotamab clezutoclax | ABBV-155 | Phase 1 Clinical | Abbvie Inc | Solid tumours | Details |
SCRI-CARB7H3 | SCRI-CARB7H3 | Phase 1 Clinical | Seattle Children'S Hospital | Neuroblastoma; Choroid Plexus Neoplasms; Neoplasms, Germ Cell and Embryonal; Melanoma; Glioma; Diffuse Intrinsic Pontine Glioma; Neuroectodermal Tumors, Primitive; Sarcoma; Sarcoma, Clear Cell; Neurofibrosarcoma; Sarcoma, Ewing; Osteosarcoma; Retinoblastoma; Teratoma; Sarcoma, Synovial; Central Nervous System Neoplasms; Wilms Tumor; Diffuse midline glioma; Hepatoblastoma; Rhabdoid Tumor; Desmoplastic Small Round Cell Tumor; Carcinoma; Rhabdomyosarcoma; Medulloblastoma; Solid tumours; Ependymoma | Details |
CC-3 | CC-3 | Phase 1 Clinical | Eberhard Karls University Of Tubingen, Germany | Colorectal Neoplasms; Gastrointestinal Neoplasms | Details |
KT-095 | KT-095 | Phase 1 Clinical | Nanjing Kati Medical Technology Co Ltd | Solid tumours | Details |
EX-105 | EX-105; EX105 | Phase 1 Clinical | Guangzhou Excelmab Inc | Solid tumours | Details |
MGC-026 | MGC026; MGC-026 | Phase 1 Clinical | Macrogenics Inc | Prostatic Neoplasms, Castration-Resistant; Uterine Cervical Neoplasms; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Melanoma; Endometrial Neoplasms; Colorectal Neoplasms; Sarcoma; Urinary Bladder Neoplasms; Ovarian Neoplasms; Neoplasms; Small Cell Lung Carcinoma; Pancreatic Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Solid tumours | Details |
Loco-regional B7H3 IL-7Ra CAR T Cell therapy(Chulalongkorn University) | Phase 1 Clinical | Chulalongkorn University, King Chulalongkorn Memorial Hospital | Brain Neoplasms; Diffuse Intrinsic Pontine Glioma | Details | |
Autologous CAR-T Cells Targeting B7-H3(Unc Lineberger Comprehensive Cancer Center) | Phase 1 Clinical | Unc Lineberger Comprehensive Cancer Center | Ovarian Neoplasms; Pancreatic Neoplasms; Carcinoma, Ovarian Epithelial; Triple Negative Breast Neoplasms; Neoplasms; Breast Neoplasms | Details | |
MT-027 | MT-027 | Phase 1 Clinical | T-Maximum Pharmaceutical (Suzhou) Co Ltd | Glioma | Details |
UTAA06 | UTAA-06 | Phase 1 Clinical | Persongen Biotherapeutics (Suzhou) Co Ltd | Leukemia, Myeloid, Acute | Details |
B7-H3 CAR T-cell therapy(Stanford University) | B7-H3CART | Phase 1 Clinical | Stanford University | Nervous System Diseases | Details |
TX103 CAR-T cell therapy(Fuzhou Tuoxin Tiancheng Biotechnology) | Phase 1 Clinical | Fuzhou Tuoxin Tiancheng Biotechnology Co Ltd | Solid tumours; Glioma | Details | |
EGFR/B7H3 CAR-T | EGFR/B7H3 CAR-T | Phase 1 Clinical | Second Affiliated Hospital Of Guangzhou Medical University | Triple Negative Breast Neoplasms; Lung Neoplasms | Details |
BAT-8009 | BAT8009; BAT-8009 | Phase 1 Clinical | Bio-Thera Solutions Ltd | Solid tumours | Details |
TAA-06 | TAA06-UCAR-γδT; TAA-06 | Phase 1 Clinical | Persongen Biotherapeutics (Suzhou) Co Ltd | Solid tumours; Neuroblastoma; Colorectal Neoplasms; Lung Neoplasms; Melanoma | Details |
XmAb-808 | XmAb808 | Phase 1 Clinical | Xencor Inc | Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Transitional Cell; Carcinoma, Ovarian Epithelial; Triple Negative Breast Neoplasms; Prostatic Neoplasms, Castration-Resistant; Colorectal Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung | Details |
Anti-CD276 CAR T-cell therapy (Persongen ) | Phase 1 Clinical | Persongen Biotherapeutics (Suzhou) Co Ltd | Stomach Neoplasms; Small Cell Lung Carcinoma; Osteosarcoma; Neuroblastoma; Lung Neoplasms | Details | |
B7-H3-targeting CAR-T cell therapy | Beijing Tiantan Hospital, Capital Medical University | Details |
This web search service is supported by Google Inc.